Our mission is to serve as a vehicle for the open exchange of ideas that drive science and new innovations. Our vision is to catalyze the development of the next generation of innovative treatment and technologies that will improve health and save lives. Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishme
nt of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media. Our non-profit 501(c)(3) Foundation oversees and directs activities in the United States for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. Founded in France 50 years ago by pharmacist Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien supports, recognizes and awards the efforts of scientists, researchers and companies committed to advancing medical innovation with the power to change the human condition. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
